Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565341 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
A NA study of Melasma, sponsored by Focus Medical.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03565341: Completed NA study of Melasma, sponsored by Focus Medical.
NCT03565341 is a NA study of Melasma that has completed, run by Focus Medical. The registered enrollment target is 20 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03565341, a NA study of Melasma, has completed, sponsored by Focus Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.
Primary Outcome
The study will be deemed successful if the point estimate of the percent of successful subjects will be at least 50%.
Conditions Studied
Interventions
- DEVICE PiQo4
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Skin Laser & Surgery Specialists Of NY & NJ - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2019-08-08 |
| Phase | NA |
What the finished NCT03565341 record still lists
NCT03565341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which PiQo4 is the first listed.
NCT03565341 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03565341 about?
NCT03565341 is a clinical study titled "Efficacy and Safety of PiQo4 Device for Treatment of Melasma". Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 mo...
What is the current status of trial NCT03565341?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-07-02. Estimated completion is 2019-08-08.
What conditions does trial NCT03565341 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT03565341?
The interventions under investigation include: PiQo4 (DEVICE).
Who is sponsoring clinical trial NCT03565341?
This trial is sponsored by Focus Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03565341 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03565341's enrollment target sits among peer trials
20 4th of 8 higher than 4 of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI